484 related articles for article (PubMed ID: 16421019)
1. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
2. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
Chen PW; Uno T; Ksander BR
Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898
[TBL] [Abstract][Full Text] [Related]
3. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites.
Ksander BR; Streilein JW
J Immunol; 1990 Oct; 145(7):2057-63. PubMed ID: 1975822
[TBL] [Abstract][Full Text] [Related]
4. Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner.
Dace DS; Chen PW; Alizadeh H; Niederkorn JY
J Leukoc Biol; 2007 Feb; 81(2):421-9. PubMed ID: 17077163
[TBL] [Abstract][Full Text] [Related]
5. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
Wenkel H; Chen PW; Ksander BR; Streilein JW
Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3202-8. PubMed ID: 10586943
[TBL] [Abstract][Full Text] [Related]
6. Local T helper cell signals by lymphocytes infiltrating intraocular tumors.
Ksander BR; Acevedo J; Streilein JW
J Immunol; 1992 Mar; 148(6):1955-63. PubMed ID: 1531848
[TBL] [Abstract][Full Text] [Related]
7. Successful immunotherapy of an intraocular tumor in mice.
Schurmans LR; den Boer AT; Diehl L; van der Voort EI; Kast WM; Melief CJ; Toes RE; Jager MJ
Cancer Res; 1999 Oct; 59(20):5250-4. PubMed ID: 10537305
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses.
Liu Y; Bi X; Xu S; Xiang J
Cancer Res; 2005 Jun; 65(11):4955-62. PubMed ID: 15930318
[TBL] [Abstract][Full Text] [Related]
9. Complete elimination ('cure') of progressively growing intraocular tumors by local injection of tumor-specific CD8+ T lymphocytes.
Miki S; Ksander B; Streilein JW
Invest Ophthalmol Vis Sci; 1993 Dec; 34(13):3622-34. PubMed ID: 8258521
[TBL] [Abstract][Full Text] [Related]
10. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
[TBL] [Abstract][Full Text] [Related]
11. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses.
Niederkorn JY; Streilein JW
J Immunol; 1983 Dec; 131(6):2670-4. PubMed ID: 6196396
[TBL] [Abstract][Full Text] [Related]
12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
13. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
14. Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors.
Ksander BR; Bando Y; Acevedo J; Streilein JW
Cancer Res; 1991 Jun; 51(12):3153-8. PubMed ID: 1904003
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.
Streilein JW; Niederkorn JY
J Immunol; 1985 Mar; 134(3):1381-7. PubMed ID: 3155766
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous immune rejection of intraocular tumors in mice.
Niederkorn JY; Meunier PC
Invest Ophthalmol Vis Sci; 1985 Jun; 26(6):877-84. PubMed ID: 3924853
[TBL] [Abstract][Full Text] [Related]
17. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
18. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
Cayeux S; Beck C; Aicher A; Dörken B; Blankenstein T
Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119
[TBL] [Abstract][Full Text] [Related]
19. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
Hiroishi K; Tüting T; Tahara H; Lotze MT
Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
